Watch ALK Gene Alterations and Genomic Testing: Oncology Hour featuring expert oncologists Dr. Jason Freedman and Dr. Ted Laetsch. Dr. Jason Freedman specializes in pediatric oncology and has contributed to the development of clinical guidelines to standardize management of symptoms and toxicities associated with cancer therapy and stem cell transplant. Dr. Ted Laetsch leads clinical and translational research evaluating novel targeted and immunotherapies for children with high-risk and often ultra-rare cancers. He is also active in early phase drug development nationally and internationally, with a particular focus on molecularly targeted therapies. Like the Massive Bio Facebook page to get notified about future events with our oncology experts. Fill out the form on this page to watch the full event.
Topics that were covered during the event include:
Clinical trials test the latest scientific advancements in treatments for alterations such as ALK. Patients who choose to enroll in trials can receive cutting-edge treatment and high-quality care under the direction of scientists, doctors, and researchers. Cancer patients might gain access to promising drugs and innovative treatments long before they’re made available to the public. During the event, we took questions directly from the community on topics such as clinical trials, ALK gene alterations, genomic testing, and targeted therapies. At the end of the event, you can watch the live Q&A answered all submissions.
With Massive Bio’s AI technology, finding a clinical trial doesn’t have to be difficult or time consuming for patients or their physicians. Let us help you and your patients find the best trial within 48 hours of receipt of records. ALK Gene Alterations and Genomic Testing: Oncology Hour was hosted live on Tuesday, December 28th at 11:00 am EST. Fill out the form to watch the full event. Tune in to learn about ALK Fusion Clinical Trials, genomic testing, how Massive Bio can help patients with ALK gene alterations, and more!